FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:CCT8-LHX4

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: CCT8-LHX4
FusionPDB ID: 14358
FusionGDB2.0 ID: 14358
HgeneTgene
Gene symbol

CCT8

LHX4

Gene ID

10694

89884

Gene namechaperonin containing TCP1 subunit 8LIM homeobox 4
SynonymsC21orf112|Cctq|D21S246|PRED71CPHD4
Cytomap

21q21.3

1q25.2

Type of geneprotein-codingprotein-coding
DescriptionT-complex protein 1 subunit thetaCCT-thetaTCP-1-thetachaperonin containing T-complex polypeptide 1 subunit 8chaperonin containing TCP1, subunit 8 (theta)renal carcinoma antigen NY-REN-15LIM/homeobox protein Lhx4LIM homeobox protein 4
Modification date2020032020200313
UniProtAcc

P50990

Main function of 5'-partner protein: FUNCTION: Component of the chaperonin-containing T-complex (TRiC), a molecular chaperone complex that assists the folding of proteins upon ATP hydrolysis (PubMed:25467444). The TRiC complex mediates the folding of WRAP53/TCAB1, thereby regulating telomere maintenance (PubMed:25467444). As part of the TRiC complex may play a role in the assembly of BBSome, a complex involved in ciliogenesis regulating transports vesicles to the cilia (PubMed:20080638). The TRiC complex plays a role in the folding of actin and tubulin (Probable). {ECO:0000269|PubMed:20080638, ECO:0000269|PubMed:25467444, ECO:0000305}.

Q969G2

Main function of 5'-partner protein: FUNCTION: May play a critical role in the development of respiratory control mechanisms and in the normal growth and maturation of the lung. Binds preferentially to methylated DNA (PubMed:28473536). {ECO:0000250, ECO:0000269|PubMed:28473536}.
Ensembl transtripts involved in fusion geneENST idsENST00000470450, ENST00000286788, 
ENST00000540844, ENST00000542732, 
ENST00000263726, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score6 X 6 X 2=723 X 3 X 5=45
# samples 67
** MAII scorelog2(6/72*10)=-0.263034405833794
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(7/45*10)=0.637429920615292
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
Fusion gene context

PubMed: CCT8 [Title/Abstract] AND LHX4 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: CCT8 [Title/Abstract] AND LHX4 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)CCT8(30432862)-LHX4(180217420), # samples:3
Anticipated loss of major functional domain due to fusion event.CCT8-LHX4 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
CCT8-LHX4 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
CCT8-LHX4 seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
CCT8-LHX4 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
CCT8-LHX4 seems lost the major protein functional domain in Tgene partner, which is a transcription factor due to the frame-shifted ORF.
CCT8-LHX4 seems lost the major protein functional domain in Tgene partner, which is a tumor suppressor due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneLHX4

GO:0045944

positive regulation of transcription by RNA polymerase II

15998782



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr21:30432862/chr1:180217420)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across CCT8 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across LHX4 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000542732CCT8chr2130432862-ENST00000263726LHX4chr1180217420+840116381261691521
ENST00000542732CCT8chr2130432861-ENST00000263726LHX4chr1180217419+840116381261691521

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000542732ENST00000263726CCT8chr2130432862-LHX4chr1180217420+0.0021622370.99783784
ENST00000542732ENST00000263726CCT8chr2130432861-LHX4chr1180217419+0.0021622370.99783784

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for CCT8-LHX4

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
CCT8chr2130432861LHX4chr11802174191638503LATNAAVTVLRVDQRFPSALAATSTS
CCT8chr2130432862LHX4chr11802174201638503LATNAAVTVLRVDQRFPSALAATSTS

Top

Potential FusionNeoAntigen Information of CCT8-LHX4 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CCT8-LHX4_30432861_180217419.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CCT8-LHX4chr2130432861chr11802174191638HLA-B14:02DQRFPSAL0.99990.89471220
CCT8-LHX4chr2130432861chr11802174191638HLA-B14:01DQRFPSAL0.99990.89471220
CCT8-LHX4chr2130432861chr11802174191638HLA-B15:37DQRFPSAL0.99930.69511220
CCT8-LHX4chr2130432861chr11802174191638HLA-B15:17TVLRVDQRF0.97470.7559716
CCT8-LHX4chr2130432861chr11802174191638HLA-A30:08RVDQRFPSA0.92910.77671019
CCT8-LHX4chr2130432861chr11802174191638HLA-B57:03TVLRVDQRF0.92810.905716
CCT8-LHX4chr2130432861chr11802174191638HLA-B08:09RVDQRFPSA0.78550.79021019
CCT8-LHX4chr2130432861chr11802174191638HLA-A32:13TVLRVDQRF0.62680.7896716
CCT8-LHX4chr2130432861chr11802174191638HLA-B57:01VTVLRVDQRF0.99980.822616
CCT8-LHX4chr2130432861chr11802174191638HLA-B57:03VTVLRVDQRF0.99810.7775616
CCT8-LHX4chr2130432861chr11802174191638HLA-B39:06DQRFPSALAA0.99250.97491222
CCT8-LHX4chr2130432861chr11802174191638HLA-B27:07LRVDQRFPSAL10.6381920
CCT8-LHX4chr2130432861chr11802174191638HLA-B39:06VDQRFPSALAA0.99180.96211122
CCT8-LHX4chr2130432861chr11802174191638HLA-A30:08RVDQRFPSALA0.98140.77191021
CCT8-LHX4chr2130432861chr11802174191638HLA-B14:03DQRFPSAL0.9990.88961220
CCT8-LHX4chr2130432861chr11802174191638HLA-B51:07DQRFPSAL0.98750.86311220
CCT8-LHX4chr2130432861chr11802174191638HLA-B39:08VDQRFPSAL0.850.93261120
CCT8-LHX4chr2130432861chr11802174191638HLA-C05:09RVDQRFPSAL10.96861020
CCT8-LHX4chr2130432861chr11802174191638HLA-C08:15RVDQRFPSAL0.99990.97711020
CCT8-LHX4chr2130432861chr11802174191638HLA-B73:01LRVDQRFPSA0.99840.8212919
CCT8-LHX4chr2130432861chr11802174191638HLA-B73:01DQRFPSALAA0.97440.92661222
CCT8-LHX4chr2130432861chr11802174191638HLA-B73:01VDQRFPSALAA0.99540.91631122
CCT8-LHX4chr2130432861chr11802174191638HLA-B73:01DQRFPSALAAT0.99470.95241223
CCT8-LHX4chr2130432861chr11802174191638HLA-B15:13TVLRVDQRF0.90290.5752716
CCT8-LHX4chr2130432861chr11802174191638HLA-B57:02TVLRVDQRF0.840.7127716
CCT8-LHX4chr2130432861chr11802174191638HLA-C05:01RVDQRFPSAL10.96861020
CCT8-LHX4chr2130432861chr11802174191638HLA-C04:03RVDQRFPSAL10.95271020
CCT8-LHX4chr2130432861chr11802174191638HLA-C08:02RVDQRFPSAL0.99990.97711020
CCT8-LHX4chr2130432861chr11802174191638HLA-B57:10VTVLRVDQRF0.99980.822616
CCT8-LHX4chr2130432861chr11802174191638HLA-B57:02VTVLRVDQRF0.99610.6871616
CCT8-LHX4chr2130432861chr11802174191638HLA-B07:13RVDQRFPSAL0.99120.90551020
CCT8-LHX4chr2130432861chr11802174191638HLA-B27:06LRVDQRFPSAL10.7446920

Top

Potential FusionNeoAntigen Information of CCT8-LHX4 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CCT8-LHX4_30432861_180217419.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CCT8-LHX4chr2130432861chr11802174191638DRB1-0301VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0301AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0301AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0301TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0303VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0303AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0303AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0303TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0305VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0305AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0305AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0307VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0307AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0307AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0307TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0310VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0310AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0310AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0313VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0313AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0313AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0313TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0315VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0315AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0315AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0315TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0318VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0318AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0318AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0318TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0320VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0320AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0320AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0320TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0322VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0322AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0322AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0322TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0324VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0324AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0324AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0324TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0326VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0326AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0326AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0326TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0328VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0328AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0328AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0328TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0330VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0330AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0330AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0330TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0332VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0332AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0332AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0332TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0334VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0334AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0334AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0334TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0336VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0336AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0336AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0336TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0340VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0340AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0340AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0342VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0342AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0342AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0344VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0344AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0344AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0344TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0346VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0346AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0346AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0346TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0348VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0348AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0348AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0348TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0350VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0350AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0350AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0350TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0352VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0352AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0352AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0352TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-0354VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-0354AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-0354AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-0354TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-1107VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1107AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-1107AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-1107TVLRVDQRFPSALAA722
CCT8-LHX4chr2130432861chr11802174191638DRB1-1134VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1153VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1173VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1179VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1179AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-1179AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-1182VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1183VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1333VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1333AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-1337VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1337AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-1344VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1381VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1385VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1394VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1394AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-1394AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-1406VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1409VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1417VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1419VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1419AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-1420VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1421VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1421AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-1421AAVTVLRVDQRFPSA419
CCT8-LHX4chr2130432861chr11802174191638DRB1-1424VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1429VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1430VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1434VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1437VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1437AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-1480VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1480AVTVLRVDQRFPSAL520
CCT8-LHX4chr2130432861chr11802174191638DRB1-1483VTVLRVDQRFPSALA621
CCT8-LHX4chr2130432861chr11802174191638DRB1-1495VTVLRVDQRFPSALA621

Top

Fusion breakpoint peptide structures of CCT8-LHX4

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
10333VTVLRVDQRFPSALCCT8LHX4chr2130432861chr11802174191638

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CCT8-LHX4

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN10333VTVLRVDQRFPSAL-6.18902-6.30242
HLA-B14:023BVN10333VTVLRVDQRFPSAL-5.51674-6.55204
HLA-B52:013W3910333VTVLRVDQRFPSAL-6.26372-6.37712
HLA-B52:013W3910333VTVLRVDQRFPSAL-2.88933-3.92463
HLA-A11:014UQ210333VTVLRVDQRFPSAL-8.95966-9.99496
HLA-A24:025HGA10333VTVLRVDQRFPSAL-7.97421-8.08761
HLA-A24:025HGA10333VTVLRVDQRFPSAL-4.46014-5.49544
HLA-B44:053DX810333VTVLRVDQRFPSAL-4.21738-4.33078
HLA-B44:053DX810333VTVLRVDQRFPSAL-3.79801-4.83331
HLA-B35:011A1N10333VTVLRVDQRFPSAL-5.60863-5.72203
HLA-B35:011A1N10333VTVLRVDQRFPSAL-5.44414-6.47944
HLA-A02:016TDR10333VTVLRVDQRFPSAL-6.07498-7.11028

Top

Vaccine Design for the FusionNeoAntigens of CCT8-LHX4

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
CCT8-LHX4chr2130432861chr11802174191019RVDQRFPSAGTGGATCAGAGATTCCCCAGTGCGCTG
CCT8-LHX4chr2130432861chr11802174191020RVDQRFPSALGTGGATCAGAGATTCCCCAGTGCGCTGGCT
CCT8-LHX4chr2130432861chr11802174191021RVDQRFPSALAGTGGATCAGAGATTCCCCAGTGCGCTGGCTGCA
CCT8-LHX4chr2130432861chr11802174191120VDQRFPSALGATCAGAGATTCCCCAGTGCGCTGGCT
CCT8-LHX4chr2130432861chr11802174191122VDQRFPSALAAGATCAGAGATTCCCCAGTGCGCTGGCTGCAACC
CCT8-LHX4chr2130432861chr11802174191220DQRFPSALCAGAGATTCCCCAGTGCGCTGGCT
CCT8-LHX4chr2130432861chr11802174191222DQRFPSALAACAGAGATTCCCCAGTGCGCTGGCTGCAACC
CCT8-LHX4chr2130432861chr11802174191223DQRFPSALAATCAGAGATTCCCCAGTGCGCTGGCTGCAACCAGC
CCT8-LHX4chr2130432861chr1180217419616VTVLRVDQRFACTGTACTTAGAGTGGATCAGAGATTCCCC
CCT8-LHX4chr2130432861chr1180217419716TVLRVDQRFGTACTTAGAGTGGATCAGAGATTCCCC
CCT8-LHX4chr2130432861chr1180217419919LRVDQRFPSAAGAGTGGATCAGAGATTCCCCAGTGCGCTG
CCT8-LHX4chr2130432861chr1180217419920LRVDQRFPSALAGAGTGGATCAGAGATTCCCCAGTGCGCTGGCT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
CCT8-LHX4chr2130432861chr1180217419419AAVTVLRVDQRFPSAGCAGTCACTGTACTTAGAGTGGATCAGAGATTCCCCAGTGCGCTG
CCT8-LHX4chr2130432861chr1180217419520AVTVLRVDQRFPSALGTCACTGTACTTAGAGTGGATCAGAGATTCCCCAGTGCGCTGGCT
CCT8-LHX4chr2130432861chr1180217419621VTVLRVDQRFPSALAACTGTACTTAGAGTGGATCAGAGATTCCCCAGTGCGCTGGCTGCA
CCT8-LHX4chr2130432861chr1180217419722TVLRVDQRFPSALAAGTACTTAGAGTGGATCAGAGATTCCCCAGTGCGCTGGCTGCAACC

Top

Information of the samples that have these potential fusion neoantigens of CCT8-LHX4

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCACCT8-LHX4chr2130432861ENST00000542732chr1180217419ENST00000263726TCGA-EW-A6SA

Top

Potential target of CAR-T therapy development for CCT8-LHX4

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to CCT8-LHX4

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to CCT8-LHX4

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource